1733-P

Two-year real-world effectiveness of semaglutide in patients with obesity or overweight

[Link]
ada2025/[Link]

Aleksandrina Ruseva, Wojciech Michalak, Anthony Fabricatore, Bríain Ó Hartaigh, Julia Wang, Zhenxiang Zhao
Novo Nordisk Inc., Plainsboro, NJ, USA.

In this real-world study, patients with obesity or overweight who were Percent change in mean body weight

treated with semaglutide for a 2-year follow-up period demonstrated −16.2% Semaglutide 1.7 and/or 2.4 mg,

a clinically relevant and sustained reduction in body weight 2-year follow-up period

Aim Key results Summary

• Semaglutide is a glucagon-like peptide-1 receptor • Overall, 2639 patients met the eligibility Table 1: Baseline demographic and clinical characteristics
Figure 1: Patients achieving a reduction in body weight of ≥5%, ≥10%, ≥15%, and ≥20% from • This retrospective cohort study demonstrated
agonist indicated for chronic weight management criteria for the study, with body weight Patients with reported body weight baseline at 2 years of follow-up that adults with obesity or overweight who
as an adjunct to a reduced calorie diet and increased and/or BMI outcomes reported for Overall cohort and/or BMI outcomes received a semaglutide injection achieved
physical activity in patients with obesity or overweight 370 (13.7%) patients Characteristic (N = 2639) (n = 370)
clinically significant and sustained reduction
Age, mean (SD), years 47.8 (9.7) 49.0 (9.7)
and ≥1 weight-related comorbidity1-2 • Demographic and clinical characteristics are in their body weight and BMI over a 2-year period
Female, n (%) 2052 (77.7) 295 (79.7)
• This study aimed to examine the real-world impact shown in Table 1 Body weight
of semaglutide on change in body weight and body – Among patients with reported body
n 179 179
mass index (BMI) over a 2-year follow-up period in
weight and/or BMI outcomes, the mean
Mean (SD), kg
BMIa
109 (22.3) 109 (22.3) Conclusions
patients who initiated semaglutide injection 2.4 mg age at baseline was 49.0 years and most
(Wegovy®) for chronic weight management n 2639 370
patients were 35 to 44 years of age Mean (SD), kg/m2 35.7 (5.0) 37.2 (5.1) • In this real-world study, clinically relevant and
(24.9%), 45 to 54 years of age (35.7%), BMI class (BMI range), n (%) sustained reductions in both body weight and
or 55 to 64 years of age (28.6%) Overweight (25.0-29.9 kg/m2) 96 (3.6) 17 (4.6) BMI were observed in patients who received
Methods – Most (79.7%) patients were female
Obesity class I (30.0-34.9 kg/m2) 1075 (40.7) 98 (26.5)
continuous treatment with semaglutide
Obesity class II (35.0-39.9 kg/m2) 535 (20.3) 131 (35.4)
Obesity class III (≥40.0 kg/m2) 933 (35.4) 124 (33.5)
1.7 and/or 2.4 mg for 2 years, with patients
– The mean BMI was 37.2 kg/m2, which is
• This retrospective cohort study utilized electronic Race/ethnicity, n (%) going down 1 BMI class on average
indicative of obesity class II
medical records and claims data (2012-2024) from n 2067 318
• These results are consistent with results from
the US-based Komodo Health database • Among the 179 patients with available White 1381 (66.8) 206 (64.8)
the STEP 5 clinical trial of semaglutide 2.4 mg
body weight outcomes, the mean (SD) Black or African American 205 (9.9) 48 (15.1)
• Eligible patients were ≥18 years of age; had absolute and percent changes from Hispanic or Latino 166 (8.0) 25 (7.9) at 2 years (weight loss: −15.2%; BMI reduction:
obesity (BMI: ≥30 kg/m2) or were overweight Asian or Pacific Islander 30 (1.5) 6 (1.9) Figure 2: Change in mean BMI from baseline at 2 years of follow-up −5.9 kg/m2)3 and extend beyond prior real-world
baseline in body weight at 2 years were
(BMI: 25-29.9 kg/m2) with ≥1 weight-related −17.5 (10.2) kg and −16.2% (9.6), Other/unknown 285 (13.8) 33 (10.4) studies, which demonstrated notable reductions
comorbidity; had initiated semaglutide between respectively (P <0.0001) Insurance type in body weight during shorter follow-up periods
June 15, 2021, and August 31, 2022; and had Commercial 2465 (93.4) 343 (92.7)
• Most (90.5%) patients achieved a ≥5% Medicare 62 (2.3) 16 (4.3) • Key limitations of this study include the potential
escalated to the maintenance dose of a once-weekly
reduction in body weight from baseline at Medicaid 74 (2.8) 5 (1.4) introduction of bias related to patient selection
semaglutide injection of 1.7 and/or 2.4 mg for
2 years, while nearly half (46.9%) achieved a Other/missing 38 (1.4) 6 (1.6) and the lack of a comparator cohort
≥2 years (allowing for a ≤60-day gap)
≥15% reduction in body weight and 29.6% Comorbiditiesb
• Patients were required to have available claims data Dyslipidemia 991 (37.6) 161 (43.5)
• Overall, these findings show that continuous
achieved a ≥20% reduction in body weight treatment with semaglutide 1.7 and/or 2.4 mg is
for 6 months prior to and ≥2 years after the first Hypertension 966 (36.6) 137 (37.0)
(Figure 1) associated with long-term weight loss, which
semaglutide 2.4 mg claim (index date) Musculoskeletal pain 961 (36.4) 152 (41.1)
• Among the 369 patients with available Prediabetes 626 (23.7) 101 (27.3) aligns with current guideline recommendations
• Descriptive statistics were utilized to summarize Obstructive sleep apnea 471 (17.8) 81 (21.9) for the use of anti-obesity medications in
BMI outcomes, the mean (SD) absolute
baseline characteristics, follow-up measurements, change in BMI from baseline at 2 years BMI, body mass index. conjunction with lifestyle changes to effectively
BMI, body mass index.
and changes in outcomes was −5.9 (4.0) kg/m2 (P <0.0001; Figure 2)
aIf BMI was not reported but height and body weight data were available, then BMI was calculated.
bThe 5 most prevalent comorbidities have been included. manage obesity and its associated health risks1-2
References Acknowledgments Disclosures
1. Wegovy® (semaglutide) injection 2.4 mg [package insert]. Novo Nordisk Inc.; 2024. This study was sponsored by Novo Nordisk Inc. Editorial and medical writing support were provided by Jessica A. Weaver, PhD, All authors are employees and shareholders of Novo Nordisk Inc.
2. US Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. Accessed March 28, 2025. of Lumanity Communications Inc., and were funded by Novo Nordisk Inc.
[Link]
(Archived in Pagefreezer.)
Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA); June 20-23, 2025; Chicago, IL, USA. 3. Garvey WT, et al. Nat Med. 2022;28(10):2083-2091.